Century Therapeutics Inc (NASDAQ:IPSC) reported its financial results for the fourth quarter and full year ended December 31, 2025. The company, a biotechnology firm focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies, posted a net loss that was significantly narrower than the previous year, driven largely by a substantial collaboration payment.
Earnings and Revenue Versus Estimates
For the fourth quarter of 2025, Century reported no revenue, which was in line with analyst expectations of $0.0 million. The company's non-GAAP earnings per share (EPS) came in at a loss of $0.25. This result surpassed the consensus estimate, which anticipated a deeper loss of $0.289 per share.
The market reaction to the report has been notably positive in pre-market trading, with shares rising approximately 1.8%. This upward move suggests investor relief at the narrower-than-expected quarterly loss and a favorable reception to the broader business updates.
Full Year 2025 Financial Snapshot
The annual results highlight a transformative year for Century's financials, primarily due to its collaboration with Bristol-Myers Squibb.
- Collaboration Revenue: $109.2 million for FY 2025, a dramatic increase from $6.6 million in FY 2024.
- Net Loss: $9.6 million, a substantial improvement from a net loss of $126.6 million in the prior year.
- Cash Position: The company ended the year with $117.1 million in cash, cash equivalents, and marketable securities. Crucially, management noted that this balance, combined with the net proceeds from a $135 million private placement completed in January 2026, extends its cash runway into the first quarter of 2029.
Pipeline Progress and Strategic Highlights
The earnings release placed heavy emphasis on pipeline advancement, which remains the core value driver for the pre-revenue company.
CNTY-813 for Type 1 Diabetes: This beta islet cell therapy program, described as the company's top priority, is advancing through Investigational New Drug (IND)-enabling studies. Century reiterated its plan to submit an IND in the fourth quarter of 2026, with initial clinical data anticipated in the second half of 2027. The company highlighted compelling preclinical data showing sustained glucose control in animal models for over six months.
CNTY-308 for B-Cell Malignancies: This CD19-targeted CAR-iT cell therapy program remains on track to enter the clinic in 2026, pending completion of IND-enabling studies and regulatory clearance.
Strengthened Balance Sheet: The oversubscribed $135 million private financing in January, led by new investor TCGX with participation from other institutional investors, was a key highlight. This capital infusion provides the company with an extended operational runway well into the next decade, de-risking its path to critical clinical milestones.
Looking Ahead
The company did not provide specific financial guidance for 2026 in the release. Analyst estimates project the company will continue to operate without product sales in the coming year, with a consensus EPS loss forecast of $0.586 for the full year 2026. For the first quarter of 2026, analysts estimate an EPS loss of $0.173 on zero revenue.
The positive pre-market reaction appears to be less about a quarterly earnings beat and more a vote of confidence in Century's refined strategy, clear pipeline timelines, and significantly fortified financial position. With a cash runway now extending into early 2029, the company has bought itself ample time to execute on its lead programs without the immediate overhang of dilution risk.
For a detailed look at historical earnings and future analyst projections, you can review the data here: Historical Earnings | Analyst Estimates & Forecasts
Disclaimer: This article is for informational purposes only and does not constitute investment advice, nor does it recommend the purchase or sale of any security. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.